Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection

被引:47
作者
Rea, Mary C. [1 ,2 ]
Alemayehu, Debebe [1 ,2 ]
Ross, R. Paul [1 ,2 ]
Hill, Colin [2 ,3 ]
机构
[1] TEAGASC, Food Res Ctr, Fermoy, Cork, Ireland
[2] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland
[3] Natl Univ Ireland Univ Coll Cork, Dept Microbiol, Cork, Ireland
关键词
ANTIBIOTIC-ASSOCIATED DIARRHEA; PLACEBO-CONTROLLED TRIAL; PSEUDOMONAS-AERUGINOSA; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-BOULARDII; TOXIN PRODUCTION; NARROW-SPECTRUM; DISEASE; MICROBIOTA; MODEL;
D O I
10.1099/jmm.0.058933-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Clostridium difficile infection (CD is a major cause of morbidity and mortality among hospitalized patients and imposes a considerable financial burden on health service providers in both Europe and the USA. The incidence of CDI has dramatically increased in recent years, partly due to the emergence of a number of hypervirulent strains. The most commonly documented risk factors associated with CDIs are antibiotic usage leading to alterations of the gut microbiota, age >65 years and long-term hospital stay. Since standard therapies for antibiotic-associated diarrhoea and CD! have limited efficacy, there is now an urgent need for alternative therapeutics. In this review, we outline the current state of play with regard to the potential of gut-derived bacteriocins, probiotics and phage to act as antimicrobial agents against CDI in the human gut.
引用
收藏
页码:1369 / 1378
页数:10
相关论文
共 79 条
[1]   Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube [J].
Aas, J ;
Gessert, CE ;
Bakken, JS .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :580-585
[2]   Antibiotic-Resistant Bugs in the 21st Century -- A Clinical Super-Challenge. [J].
Arias, Cesar A. ;
Murray, Barbara E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (05) :439-443
[3]   Antibiotic-associated diarrhea [J].
Bartlett, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (05) :334-339
[4]   In-vitro activity of nisin against clinical isolates of Clostridium difficile [J].
Bartoloni, A ;
Mantella, A ;
Goldstein, BP ;
Dei, R ;
Benedetti, M ;
Sbaragli, S ;
Paradisi, F .
JOURNAL OF CHEMOTHERAPY, 2004, 16 (02) :119-121
[5]   Generation of an actagardine A variant library through saturation mutagenesis [J].
Boakes, Steven ;
Ayala, Tania ;
Herman, Mark ;
Appleyard, Antony N. ;
Dawson, Michael J. ;
Cortes, Jesus .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2012, 95 (06) :1509-1517
[6]   Potential of Bacteriophages and Their Lysins in the Treatment of MRSA Current Status and Future Perspectives [J].
Borysowski, Jan ;
Lobocka, Malgorzata ;
Miedzybrodzki, Ryszard ;
Weber-Dabrowska, Beata ;
Gorski, Andrzej .
BIODRUGS, 2011, 25 (06) :347-355
[7]   Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits [J].
Brandl, Katharina ;
Plitas, George ;
Mihu, Coralia N. ;
Ubeda, Carles ;
Jia, Ting ;
Fleisher, Martin ;
Schnabl, Bernd ;
DeMatteo, Ronald P. ;
Pamer, Eric G. .
NATURE, 2008, 455 (7214) :804-U8
[8]  
Brazier J. S., 2008, EUROSURVEILLANCE, V13, P3
[9]   Phages and the evolution of bacterial pathogens:: From genomic rearrangements to lysogenic conversion [J].
Brüssow, H ;
Canchaya, C ;
Hardt, WD .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2004, 68 (03) :560-+
[10]  
Burke D., 2012, VIR MICR 2 16 20 JUL